DiaMedica Therapeutics Inc (DMAC) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
DiaMedica Therapeutics Inc stock (DMAC) is currently trading at $6.89. Analyst consensus price target for DMAC is $15.50. WallStSmart rates DMAC as Sell.
- DMAC PE ratio analysis and historical PE chart
- DMAC PS ratio (Price-to-Sales) history and trend
- DMAC intrinsic value — DCF, Graham Number, EPV models
- DMAC stock price prediction 2025 2026 2027 2028 2029 2030
- DMAC fair value vs current price
- DMAC insider transactions and insider buying
- Is DMAC undervalued or overvalued?
- DiaMedica Therapeutics Inc financial analysis — revenue, earnings, cash flow
- DMAC Piotroski F-Score and Altman Z-Score
- DMAC analyst price target and Smart Rating
DiaMedica Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
DiaMedica Therapeutics Inc (DMAC) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around return on equity and price/book. Significant fundamental concerns warrant caution or avoidance.
DiaMedica Therapeutics Inc (DMAC) Key Strengths (0)
Supporting Valuation Data
DiaMedica Therapeutics Inc (DMAC) Areas to Watch (4)
Company is destroying shareholder value
Very expensive at 6.8x book value
Small-cap company with higher risk but more growth potential
Moderate institutional interest at 39.78%
DiaMedica Therapeutics Inc (DMAC) Detailed Analysis Report
Overall Assessment
This company scores 11/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 0 register as strengths (avg 0/10) while 4 fall into concern territory (avg 3.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Price/Book, Market Cap. Some valuation metrics including Price/Book (6.82) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -64.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -64.10% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
DMAC Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
DMAC's Price-to-Sales ratio of 857.19x trades 168% above its historical average of 320.37x (96th percentile), historically expensive. The current valuation is 44% below its historical high of 1535.14x set in Nov 2018, and 6194% above its historical low of 13.62x in Dec 2014. Over the past 12 months, the PS ratio has expanded from ~397.9x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for DiaMedica Therapeutics Inc (DMAC) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
DiaMedica Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Free cash flow is -7M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact DiaMedica Therapeutics Inc.
Bottom Line
DiaMedica Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(3 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 10:07:03 AM
About DiaMedica Therapeutics Inc(DMAC)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis, Minnesota.